Canada: Banning Human Embryonic Stem Cells Patents – Has The CJEU Impeded Stem Cell Research?

Last Updated: February 9 2012
Article by Dina Anastas


The Court of Justice of the European Union ('CJEU') has invalided a patent concerning the use of human embryonic stem cells (hESCs)1, which required the prior destruction of human embryos, contrary to the European Patent Office ('EPO') granting practice. Raising the question whose approach is correct?

On 18 October 2011, the CJEU delivered its much anticipated decision in Oliver Brüstle v Greenpeace e.V. (case C-34/10) on a referral by the German Federal Supreme Court concerning the patentability of inventions relating to the use of hESCs. The decision as expected largely followed the opinion of the Advocate-General Bots, which was delivered in March 2011.

The CJEU, in interpreting the term 'human embryos' in Article 6 of the European Directive 98/44/EC on the legal protection of biotechnological inventions (the 'Biotechnology Directive'), ruled that an invention will not be patentable if the subject matter of the patent application requires the prior destruction of human embryos or their use as a base material, 'whatever the stage at which that takes place'. This will be so even if the subject matter claimed in the patent application makes no reference to the use of human embryos.

The decision of the CJEU applies throughout the European Union ('EU') and cannot be appealed. While the decision may have provided useful clarification as regards the interpretation of 'human embryos,' as far as patentability is concerned, opinions are sharply divided as to the correctness of the decision and its implications within Europe.


The main proceedings were initially brought in the Bundespatentgericht (German Federal Patent Court) by the environmental activist network Greenpeace in 2004 against a German patent (DE19756864) granted to neuroscientist Oliver Brüstle in 1999. The patent covers methods of isolating and purifying neural precursor cells, processes for their production from embryonic stem cells and their use for treatment of neural defects.

Greenpeace challenged Brüstle's patent on the grounds that the claims to the neural precursor cells derived from hESCs were contrary to public order and morality provisions of the German patent law, as well as they contravened the prohibition on the patentability of inventions claiming the use of human embryos for industrial or commercial purposes under Article 6(2)(c) of the Biotech Directive. The Federal Patent Court concurred and declared the patent invalid.

Brüstle appealed the decision to the Bundesgerichtshof (German Federal Court of Justice), which stayed the proceedings and referred the following questions to the CJEU for a preliminary ruling:

  1. the meaning of the term 'human embryos' in Article 6 of the Biotech Directive and the stages of development of human body it covers;
  2. the meaning and scope of the exclusion of 'uses of human embryos for industrial or commercial purposes' and whether this exclusion applies to uses in scientific research; and
  3. the extent to which the above exclusion applies to technical teachings if the use of human embryos is a necessary precondition of the teaching, even though that use does not form part of the technical teaching.

Article 6(1) of the Biotech Directive provides that inventions shall not be patentable where their commercial exploitation would be contrary to public order or morality. Article 6(2)(c) expressly excludes from patentability uses of human embryos for industrial or commercial purposes. Given the moral, ethical and religious differences of opinions among the EU Member States on what constitutes a human embryo, the term 'human embryos' was left undefined in the Biotech Directive.

CJEU's Decision and its implications

The CJEU made clear that it is up to the courts of EU Member States to decide what was contrary to public order or morality and that it will not raise questions of a medical and ethical (also religious) nature. However, the express prohibition under Article 6(2)(c) was capable of legal interpretation by the CJEU and the term 'human embryos' must have a unanimous conception and a Community understanding. The term must be understood in a wide sense accounting for respect for human dignity.

The CJEU interpreted 'human embryos' to mean any human ovum after fertilization, any non-fertilized human ovum into which the cell nucleus from a mature human cell has been transplanted, and any non-fertilized human ovum whose division and further development have been stimulated by parthenogenesis. The court felt it was necessary to import the latter two into the definition of 'human embryos,' even if these cells are not the object of fertilization, they are, by virtue of the technique used to obtain them, capable of commencing the process of development into a human being.

However, the CJEU maintained that it is up to the referring court to establish, in light of scientific development, whether a stem cell obtained at the blastocyst2 stage constitutes a 'human embryo' and therefore included in the concept of 'human embryos'. This is a modification to the point established by the Advocate General Bots, who opined that pluripotent cells fall outside the definition of 'human embryos.' This modification is indented to avoid the future patentability of pluripotent embryonic stem cells should their future manipulation and development into a human being becomes successful.

With regards to the second question (uses of human embryos for industrial or commercial purposes), the CJEU held that the use of hESCs for teaching purposes fell within the scope of the exclusion under Article 6(2)(c); since it implied an industrial or commercial application. The Court, however, carved out from this exclusion uses for therapeutic or diagnostic purposes as it is stated in Recital 42 in the preamble to the Directive:

'(42) Whereas, moreover, uses of human embryos for industrial or commercial purposes must also be excluded from patentability; whereas in any case such exclusion does not affect inventions for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it.'

Finally, the CJEU decided that Article 6(2)(c) also excludes from patentability an invention where the technical teaching requires prior destruction of human embryos or their use as base material, regardless of whether the description of the technical teaching claimed does not refer to the use of human embryos. The Court, mindful of the skilful ways in which patent claims may be drafted to exclude any reference to use and/or destruction of human embryos, extended the exclusion to cover such technical teachings.

If destruction of human embryos is key to exclusion from patentability, then one could, by implication, argue that patent applications based on hESCs available from established cell lines grown in the laboratories and stored in stem cell banks prior to the Brüstle decision, and which do not require the further destruction of human embryos, are not deemed to be immoral and therefore fall outside the patentability exclusion.

Of interest here is the 2008 decision of the Enlarged Board of Appeal of the EPO in G2/06 ('WARF Decision'). The WARF Decision also concerned the meaning of Rule 28(c) of the European Patent Convention (its equivalent provision Article 6(2)(c) of the Biotech Directive). In that decision, the EPO ruled that claims directed to products which, as described in the application at the filing date, could be prepared exclusively by a method which necessarily involved the destruction of an embryo from which the product was derived, even where the method was not part of the claim are immoral and therefore unpatentable. Notwithstanding the WARF Decision, it has been the practice of the EPO to allow patent applications based on stem cell lines that are available before May 2003 and which are filed after this date. These applications have not been deemed to be immoral by the EPO.

The complication however stems from the CJEU's confirmation of the Advocate General Bots' comments which emphasised taking the full history of the invention when deciding on the morality of the invention:

'The fact that destruction may occur at a stage long before the implementation of the invention is irrelevant.'

This seems to indicate that inventions which required the past destruction of human embryos are also deemed immoral by the CJEU and hence unpatentable. In light of the above, and since the EPO is not bound by the CJEU's decisions, it is not currently clear whether the EPO will continue with its practice or follow the CJEU'S decision. There also appears to be no indication from the Court whether the decision is retrospective, leaving entities with existing patents relating to stem cell technologies vulnerable to the CJEU decision.

Accordingly, the implications of the decision are far from clear. Many scientists have expressed deep concern about the effect that this decision may have on the European stem cell industry, not to mention its impact on academic stem cell research and its retention in Europe. Many fear that banning patents in this field will make it harder to attract investment into European stem cell companies, also leading to a 'brain drain' of researchers to the US for instance.

It also remains to be seen whether this judicial setback alone will impede the stem cell research field in Europe, and how the EU Member States will deal with the moral dilemma of funding and authorising stem cell research under conditions which they lay down. Advance in technology may make it possible to extract material from human embryos without destroying them and therefore the invention may fall outside the exclusion. Future cases may shed light on this point.


1.Stem cells are pluripotent (i.e. able to differentiate into specialized cell types and tissues) and can be obtained from both adult and embryonic tissues. They have great potential in cell based therapies and could be ultimately used in treatments to repair or replace various damaged tissues.

2. A blastocyst is an embryo that has developed for five to six days after fertilization. It is during blastocyst that totipotent cells (those are capable of developing into any cell type) give way to pluripotent cells.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.